Cargando…

An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria

BACKGROUND: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of...

Descripción completa

Detalles Bibliográficos
Autores principales: Owusu-Agyei, Seth, Asante, Kwaku Poku, Owusu, Ruth, Adjuik, Martin, Amenga-Etego, Stephen, Dosoo, David Kwame, Gyapong, John, Greenwood, Brian, Chandramohan, Daniel
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430614/
https://www.ncbi.nlm.nih.gov/pubmed/18575626
http://dx.doi.org/10.1371/journal.pone.0002530
_version_ 1782156417285750784
author Owusu-Agyei, Seth
Asante, Kwaku Poku
Owusu, Ruth
Adjuik, Martin
Amenga-Etego, Stephen
Dosoo, David Kwame
Gyapong, John
Greenwood, Brian
Chandramohan, Daniel
author_facet Owusu-Agyei, Seth
Asante, Kwaku Poku
Owusu, Ruth
Adjuik, Martin
Amenga-Etego, Stephen
Dosoo, David Kwame
Gyapong, John
Greenwood, Brian
Chandramohan, Daniel
author_sort Owusu-Agyei, Seth
collection PubMed
description BACKGROUND: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of the efficacy and safety of these three drug combinations was necessary to make evidence based drug treatment policies. METHODS: Five hundred and thirty-four, glucose-6-phosphate dehydrogenase (G6PD) normal children were randomised in blocks of 15 to the AS+AQ, AL or AS+CD groups. Administration of study drugs was supervised by project staff and the children were followed up at r home on days 1,2,3,7,14 and 28 post treatment. Parasitological and clinical failures and adverse events were compared between the study groups. MAIN FINDINGS: In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005). In the intention to treat analysis, the rate of early treatment failure was high in all three groups (AS+AQ 13.3%; AL 15.2%; and AS+CD 9.3%, p = 0.2) primarily due to vomiting. However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4) The incidence of adverse events was comparable between the groups. CONCLUSIONS: AS+AQ is an appropriate first line treatment for uncomplicated malaria in Ghana and possibly in the neighbouring countries in West Africa. The effectiveness of AL in routine programme conditions needs to be studied further in West Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00119145
format Text
id pubmed-2430614
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-24306142008-06-25 An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria Owusu-Agyei, Seth Asante, Kwaku Poku Owusu, Ruth Adjuik, Martin Amenga-Etego, Stephen Dosoo, David Kwame Gyapong, John Greenwood, Brian Chandramohan, Daniel PLoS One Research Article BACKGROUND: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of the efficacy and safety of these three drug combinations was necessary to make evidence based drug treatment policies. METHODS: Five hundred and thirty-four, glucose-6-phosphate dehydrogenase (G6PD) normal children were randomised in blocks of 15 to the AS+AQ, AL or AS+CD groups. Administration of study drugs was supervised by project staff and the children were followed up at r home on days 1,2,3,7,14 and 28 post treatment. Parasitological and clinical failures and adverse events were compared between the study groups. MAIN FINDINGS: In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005). In the intention to treat analysis, the rate of early treatment failure was high in all three groups (AS+AQ 13.3%; AL 15.2%; and AS+CD 9.3%, p = 0.2) primarily due to vomiting. However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4) The incidence of adverse events was comparable between the groups. CONCLUSIONS: AS+AQ is an appropriate first line treatment for uncomplicated malaria in Ghana and possibly in the neighbouring countries in West Africa. The effectiveness of AL in routine programme conditions needs to be studied further in West Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT00119145 Public Library of Science 2008-06-25 /pmc/articles/PMC2430614/ /pubmed/18575626 http://dx.doi.org/10.1371/journal.pone.0002530 Text en Owusu-Agyei et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Owusu-Agyei, Seth
Asante, Kwaku Poku
Owusu, Ruth
Adjuik, Martin
Amenga-Etego, Stephen
Dosoo, David Kwame
Gyapong, John
Greenwood, Brian
Chandramohan, Daniel
An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
title An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
title_full An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
title_fullStr An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
title_full_unstemmed An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
title_short An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
title_sort open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430614/
https://www.ncbi.nlm.nih.gov/pubmed/18575626
http://dx.doi.org/10.1371/journal.pone.0002530
work_keys_str_mv AT owusuagyeiseth anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT asantekwakupoku anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT owusuruth anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT adjuikmartin anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT amengaetegostephen anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT dosoodavidkwame anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT gyapongjohn anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT greenwoodbrian anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT chandramohandaniel anopenlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT owusuagyeiseth openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT asantekwakupoku openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT owusuruth openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT adjuikmartin openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT amengaetegostephen openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT dosoodavidkwame openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT gyapongjohn openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT greenwoodbrian openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria
AT chandramohandaniel openlabelrandomisedtrialofartesunateamodiaquineartesunatechlorproguanildapsoneandartemetherlumefantrineforthetreatmentofuncomplicatedmalaria